Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

593 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.
Drye LT, Spragg D, Devanand DP, Frangakis C, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Pollock BG, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG; CitAD Research Group. Drye LT, et al. Among authors: yesavage j. PLoS One. 2014 Jun 10;9(6):e98426. doi: 10.1371/journal.pone.0098426. eCollection 2014. PLoS One. 2014. PMID: 24914549 Free PMC article. Clinical Trial.
The future is now: model-based clinical trial design for Alzheimer's disease.
Romero K, Ito K, Rogers JA, Polhamus D, Qiu R, Stephenson D, Mohs R, Lalonde R, Sinha V, Wang Y, Brown D, Isaac M, Vamvakas S, Hemmings R, Pani L, Bain LJ, Corrigan B; Alzheimer's Disease Neuroimaging Initiative; Coalition Against Major Diseases. Romero K, et al. Clin Pharmacol Ther. 2015 Mar;97(3):210-4. doi: 10.1002/cpt.16. Epub 2014 Dec 27. Clin Pharmacol Ther. 2015. PMID: 25669145 Free PMC article.
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
Toledo JB, Zetterberg H, van Harten AC, Glodzik L, Martinez-Lage P, Bocchio-Chiavetto L, Rami L, Hansson O, Sperling R, Engelborghs S, Osorio RS, Vanderstichele H, Vandijck M, Hampel H, Teipl S, Moghekar A, Albert M, Hu WT, Monge Argilés JA, Gorostidi A, Teunissen CE, De Deyn PP, Hyman BT, Molinuevo JL, Frisoni GB, Linazasoro G, de Leon MJ, van der Flier WM, Scheltens P, Blennow K, Shaw LM, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative. Toledo JB, et al. Brain. 2015 Sep;138(Pt 9):2701-15. doi: 10.1093/brain/awv199. Epub 2015 Jul 27. Brain. 2015. PMID: 26220940 Free PMC article.
Adding Recognition Discriminability Index to the Delayed Recall Is Useful to Predict Conversion from Mild Cognitive Impairment to Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative.
Russo MJ, Campos J, Vázquez S, Sevlever G, Allegri RF; Alzheimer's Disease Neuroimaging Initiative. Russo MJ, et al. Front Aging Neurosci. 2017 Mar 10;9:46. doi: 10.3389/fnagi.2017.00046. eCollection 2017. Front Aging Neurosci. 2017. PMID: 28344552 Free PMC article.
18F-florbetapir Positron Emission Tomography-determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery.
Klinger RY, James OG, Borges-Neto S, Bisanar T, Li YJ, Qi W, Berger M, Terrando N, Newman MF, Doraiswamy PM, Mathew JP; Alzheimer’s Disease Neuroimaging Initiative (ADNI) Study Group; Neurologic Outcomes Research Group (NORG). Klinger RY, et al. Anesthesiology. 2018 Apr;128(4):728-744. doi: 10.1097/ALN.0000000000002103. Anesthesiology. 2018. PMID: 29389750 Free PMC article.
593 results